a·lac·ri·ty [uh-lak-ri-tee] cheerful readiness, promptness, or willingness
Europe: London BioScience Innovation Centre 2 Royal College Street London NW1 0NH
USA: Cambridge Innovation Center 1 Broadway, 14th Floor Kendall Square, Cambridge MA 02142

changing the face
of life sciences consulting


Trusted people

Steffan Stringer

Steffan has over 20 years of experience in world-leading contract research organisations and has particular expertise in Phase I and II clinical trial operations…

Read more »

Case studies

An ex-US business development strategy

Alacrita's diagnostics consultants were tasked with developing an ex-US business development strategy and identifying sources of non-dilutive finance for a well-funded venture capital funded diagnostics company.

Read more »


Alacrita has substantial expertise in antibody discovery, development and commercialisation. We have helped a number of clients assess antibody opportunities, including target and technology assessment, strategic valuation and biosimilar market positioning...

Read more »

Antibodies to treat bacterial infections

Alacrita's antibody consultants conducted a review of the potential of modern antibody technologies to treat severe bacterial infections. Alacrita detailed the challenges involved, the types of target available and conducted a review of the industry's antibody pipeline. We conducted a SWOT analysis on monoclonal antibody technologies that the client had encountered with respect to their applicability to bacterial infections, with suggestions of other technologies that the company should consider.

Read more »

Biomarker identification technology

Alacrita’s antibody consultants were engaged to help a start-up company that had developed a suite of proprietary antibody technologies to identify accessible cell surface proteins for discovery of candidate therapeutic mAb targets and/or biomarkers...

Read more »

Cancer vaccines

Alacrita has advised a number of cancer immunotherapy companies on a diverse range of projects. Examples include valuation models to support partnering discussions for a highly potent autologous cell-based cancer immunotherapy, through to clinical strategy advice for a company developing a peptide-based approach.

Read more »